Saul Malozowski, MD, PhD, MBA
Disclaimer: The views expressed in this editorial are those of the author and do not constitute an official position of the U.S. Department of Health and Human Services.
Potential Financial Conflicts of Interest: Before his employment at the National Institutes of Health, Dr. Malozowski was a medical officer at the U.S. Food and Drug Administration, during which he supervised the initial review of exenatide. He is currently a National Institute of Diabetes and Digestive and Kidney Diseases representative to a National Institutes of Health–sponsored clinical study, where exenatide has been provided free of charge by the manufacturer.
Requests for Single Reprints: Saul Malozowski, MD, PhD, MBA, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Democracy Two, 6707 Democracy Boulevard, Room 607, Bethesda, MD 20892-5460; e-mail, firstname.lastname@example.org.
Malozowski S. Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions. Ann Intern Med. 2007;146:527–528. doi: https://doi.org/10.7326/0003-4819-146-7-200704030-00009
Download citation file:
Published: Ann Intern Med. 2007;146(7):527-528.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use